Creative Medical Technology Holdings, Inc.
CELZHealthcare|Biotechnology|US
$0.62
+0.02 (+2.65%)
DCF Value
$2.94
Tangible Book / Share
$1.05
Cash / Share
$1.03
Financials
Financial Snapshot
Market Cap
$1.6M
Enterprise Value
-$5.2M
Revenue (TTM)
$3.0K
Net Income (TTM)
-$7.5M
Cash & Investments
$6.8M
Net Cash
$6.8M
Free Cash Flow (TTM)
-$6.4M
Operating CF (TTM)
-$6.4M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$6.8M
Quarterly Burn
$1.6M
Monthly Burn
$533.1K
Est. Runway
~4.3 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $221.9K | $13.7K | $304.1K | $88.6K | $98.0K | $10.7M | $18.4M | $10.0M | $5.9M | $7.2M | $6.8M | |
| Operating Cash Flow | -$445.2K | -$889.6K | -$1.1M | -$1.2M | -$434.6K | -$2.2M | -$7.8M | -$8.0M | -$5.3M | -$5.9M | -$6.4M | |
| Free Cash Flow | -$455.2K | -$889.6K | -$1.1M | -$1.2M | -$684.6K | -$2.2M | -$7.8M | -$8.1M | -$5.3M | -$5.9M | -$6.4M | |
| Capital Expenditure | -$10.0K | $0.00 | $0.00 | $3.00 | -$250.0K | $0.00 | $0.00 | -$100.0K | $0.00 | -$5.00 | $4.00 | |
| Financing Cash Flow | $677.0K | $681.5K | $1.3M | $997.7K | $693.9K | $12.8M | $15.5M | -$271.0K | $1.5M | $7.2M | $7.9M |
R&D Spending
R&D (TTM)
$3.2M
R&D Intensity
105087.4%
R&D Growth vs Prior
+39.5%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $4.8K | $124.4K | $165.5K | $164.5K | $87.8K | $88.6K | $9.0K | $11.0K | $6.0K | $3.0K | |
| R&D Expense | $85.3K | $260.1K | $96.6K | $0.00 | $0.00 | $109.2K | $6.3M | $2.0M | $2.4M | $2.3M | $3.2M | |
| R&D % of Revenue | — | 5418.4% | 77.7% | 0.0% | 0.0% | 124.4% | 7075.5% | 21896.0% | 21825.2% | 37663.3% | 105087.4% | |
| SG&A | $665.0K | $898.5K | $1.1M | $1.2M | $1.2M | $3.0M | $3.9M | $3.6M | $3.2M | $3.8M | $4.4M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $4.8K | $124.4K | $165.5K | $164.5K | $87.8K | $88.6K | $9.0K | $11.0K | $6.0K | $3.0K | |
| Cost of Revenue | $766.1K | $8.0K | $70.4K | $45.5K | $50.6K | $47.9K | $28.5K | $3.6K | $4.4K | $2.2K | $23.9K | |
| Gross Profit | -$766.1K | -$3.2K | $54.0K | $120.0K | $113.9K | $39.8K | $60.1K | $5.4K | $6.6K | $3.8K | -$20.9K | |
| R&D | $85.3K | $260.1K | $96.6K | $0.00 | $0.00 | $109.2K | $6.3M | $2.0M | $2.4M | $2.3M | $3.2M | |
| SG&A | $665.0K | $898.5K | $1.1M | $1.2M | $1.2M | $3.0M | $3.9M | $3.6M | $3.2M | $3.8M | $4.4M | |
| Operating Income | -$766.1K | -$1.2M | -$1.1M | -$1.1M | -$1.1M | -$3.1M | -$10.2M | -$5.6M | -$5.7M | -$6.1M | -$5.0M | |
| Interest Expense | $6.4K | $377.6K | $1.4M | $1.9M | $1.2M | $4.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$766.1K | -$2.7M | -$13.7M | -$8.5M | -$36.3M | $19.2M | -$10.1M | -$5.3M | -$5.5M | -$6.0M | -$7.5M | |
| Net Income | -$766.1K | -$2.7M | -$13.7M | -$8.5M | -$36.3M | $19.2M | -$10.1M | -$5.3M | -$5.5M | -$6.0M | -$7.5M | |
| EPS (Diluted) | -5471.94 | -17379.79 | -11351.33 | -5017.67 | -626.88 | 56.10 | -9.28 | -3.76 | -3.71 | -2.52 | -1.92 | |
| EBITDA | -$750.3K | -$1.2M | -$1.1M | -$6.6M | -$35.0M | $23.6M | -$10.1M | -$5.2M | -$5.4M | -$6.0M | -$4.9M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.32 | 1.09 | 1.41 | 1.48 | 2.38 | 6.66 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $221.9K | $13.7K | $304.1K | $88.6K | $98.0K | $10.7M | $8.3M | $3.5M | $5.9M | $7.2M | $6.8M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $10.1M | $6.5M | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $221.9K | $18.5K | $313.7K | $94.2K | $98.0K | $10.7M | $18.7M | $10.3M | $6.1M | $7.4M | $6.9M | |
| Total Assets | $322.5K | $203.1K | $477.2K | $530.8K | $717.8K | $11.3M | $19.2M | $10.7M | $6.7M | $7.8M | $7.3M | |
| Total Current Liabilities | $453.9K | $2.4M | $4.5M | $8.6M | $40.5M | $1.1M | $3.3M | $371.4K | $327.6K | $284.9K | $293.2K | |
| Long-Term Debt | $25.0K | $915.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $480.3K | $2.4M | $4.5M | $8.6M | $40.5M | $1.1M | $3.3M | $371.4K | $327.6K | $284.9K | $293.2K | |
| Stockholders' Equity | -$157.8K | -$2.2M | -$4.0M | -$8.1M | -$39.8M | $10.2M | $15.9M | $10.3M | $6.3M | $7.5M | $7.0M | |
| Retained Earnings | -$766.6K | -$3.4M | -$17.1M | -$25.6M | -$61.9M | -$43.7M | -$53.8M | -$59.1M | -$64.6M | -$70.6M | -$76.2M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$445.2K | -$889.6K | -$1.1M | -$1.2M | -$434.6K | -$2.2M | -$7.8M | -$8.0M | -$5.3M | -$5.9M | -$6.4M | |
| Capital Expenditure | -$10.0K | $0.00 | $0.00 | $3.00 | -$250.0K | $0.00 | $0.00 | -$100.0K | $0.00 | -$5.00 | $4.00 | |
| Free Cash Flow | -$455.2K | -$889.6K | -$1.1M | -$1.2M | -$684.6K | -$2.2M | -$7.8M | -$8.1M | -$5.3M | -$5.9M | -$6.4M | |
| Investing Cash Flow | -$10.0K | $0.00 | $0.00 | $0.00 | -$250.0K | $0.00 | -$10.1M | $3.4M | $6.3M | -$50.5K | -$22.4K | |
| Financing Cash Flow | $677.0K | $681.5K | $1.3M | $997.7K | $693.9K | $12.8M | $15.5M | -$271.0K | $1.5M | $7.2M | $7.9M | |
| Issuance of Stock | $500.0K | $100.0K | $0.00 | $0.00 | $0.00 | $14.8M | $15.5M | $0.00 | $1.6M | $7.2M | $3.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$271.0K | -$175.0K | -$10.0K | $0.00 | |
| Net Debt Issuance | $125.0K | $573.3K | $1.3M | $997.7K | $693.9K | -$1.6M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $2.6K | $144.2K | $1.9K | $0.00 | $170.3K | $595.4K | $68.7K | $36.6K | $36.6K | $3.5K | $0.00 | |
| Net Change in Cash | $221.8K | -$208.2K | $290.4K | -$215.4K | $9.4K | $10.6M | -$2.4M | -$4.9M | $2.5M | $1.3M | $1.5M |
Dilution Tracker
Shares outstanding grew 4012.1% over 5 years — significant dilution
Shares Outstanding
3M
5-Year Share Growth
+4012.1%
Stock Issuance (TTM)
$3.8M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.32 | 1.09 | 1.41 | 1.48 | 2.38 | 6.66 | |
| Change vs Prior % | — | 9.3% | 686.3% | 71.9% | 2702.0% | 460.6% | 236.5% | 28.8% | 5.2% | 61.0% | 179.6% | |
| Stock Issuance | $500.0K | $100.0K | $0.00 | $0.00 | $0.00 | $14.8M | $15.5M | $0.00 | $1.6M | $7.2M | $3.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$271.0K | -$175.0K | -$10.0K | $0.00 | |
| Stock Based Comp. | $2.6K | $144.2K | $1.9K | $0.00 | $170.3K | $595.4K | $68.7K | $36.6K | $36.6K | $3.5K | $0.00 |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | -66.7% | 43.4% | 72.5% | 69.2% | 45.4% | 67.8% | 60.0% | 60.0% | 63.4% | -697.1% | |
| Operating Margin % | — | -24537.6% | -895.7% | -682.9% | -677.7% | -3562.2% | -11562.5% | -62445.9% | -52216.9% | -102380.2% | -165569.9% | |
| Net Margin % | — | -55398.1% | -10977.2% | -5126.1% | -22082.2% | 21892.8% | -11449.3% | -58739.7% | -49940.7% | -99916.8% | -249160.1% | |
| EBITDA Margin % | — | -24204.4% | -878.7% | -3964.5% | -21294.1% | 26873.2% | -11345.3% | -57688.8% | -48936.6% | -100324.8% | -162812.5% | |
| FCF Margin % | — | -18533.8% | -845.9% | -733.0% | -416.1% | -2525.0% | -8800.2% | -90309.8% | -48193.6% | -97607.4% | -213248.6% | |
| ROE % | 485.5% | 118.9% | 341.8% | 105.1% | 91.3% | 188.0% | -63.9% | -51.1% | -86.6% | -79.8% | -102.3% | |
| ROA % | -237.5% | -1309.0% | -2861.9% | -1598.3% | -5060.8% | 170.5% | -52.9% | -49.3% | -82.4% | -76.8% | -102.7% | |
| ROIC % | 2664.4% | 68.1% | 33.6% | 16.1% | 2.9% | -30.6% | -64.6% | -54.3% | -90.6% | -81.5% | -71.1% | |
| R&D / Revenue % | — | 5418.4% | 77.7% | 0.0% | 0.0% | 124.4% | 7075.5% | 21896.0% | 21825.2% | 37663.3% | 105087.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 2491.7% | 33.0% | -0.6% | -46.7% | 1.0% | -89.8% | 22.2% | -45.5% | |
| Gross Profit | 0.0% | 99.6% | 1788.3% | 122.1% | -5.1% | -65.1% | 51.0% | -91.0% | 22.2% | -42.3% | |
| Operating Income | -3577.6% | -53.7% | 5.4% | -1.4% | 1.4% | -180.4% | -227.7% | 45.1% | -2.2% | -6.9% | |
| Net Income | -2390.4% | -247.1% | -413.5% | 37.9% | -328.2% | 152.9% | -152.8% | 47.9% | -3.9% | -9.1% | |
| EPS (Diluted) | -326.9% | -217.6% | 34.7% | 55.8% | 87.5% | 108.9% | -116.5% | 59.5% | 1.3% | 32.1% | |
| Operating Cash Flow | -2941.6% | -99.8% | -18.3% | -15.3% | 64.2% | -409.9% | -251.9% | -3.0% | 34.0% | -10.5% | |
| Free Cash Flow | -3009.9% | -95.4% | -18.3% | -15.3% | 43.6% | -223.7% | -251.9% | -4.2% | 34.8% | -10.5% | |
| R&D Expense | 0.0% | 204.8% | -62.9% | -100.0% | 0.0% | 0.0% | 5641.8% | -68.6% | 21.8% | -5.9% | |
| SG&A Expense | 3092.3% | 35.1% | 16.9% | 16.4% | -5.0% | 155.1% | 33.0% | -9.7% | -9.0% | 16.2% | |
| Total Assets | 149211.1% | -37.0% | 134.9% | 11.2% | 35.2% | 1469.9% | 70.3% | -44.2% | -37.8% | 17.1% | |
| Book Value / Share | 85.3% | -1196.8% | 77.3% | -17.5% | 82.4% | 105.7% | -63.0% | -49.4% | -41.7% | -26.3% | |
| Debt | -25.1% | 310.8% | 32.8% | 55.7% | -25.8% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 483.3% | 9.3% | 686.3% | 71.9% | 2702.0% | 460.6% | 236.5% | 28.8% | 5.2% | 61.0% |
Valuation
P/E (TTM)At Loss
P/S535.06
10Y Low / Med / High2.81 / 71.66 / 778.38
P/B0.60
10Y Low / Med / High0.26 / 0.56 / 0.63
EV/EBITDA1.07
10Y Low / Med / High0.41 / 0.42 / 0.47
EV/Revenue-1746.86
10Y Low / Med / High8.69 / 74.70 / 379.04
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$2.94
Tangible Book / Share
$1.05
Net Current Assets / Share
$2.57
Graham Net-Net
$0.99
Cash / Share
$1.03
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -63.60 | -0.50 | -0.65 | -0.04 | -0.22 | 0.30 | -0.41 | -1.23 | -0.62 | -0.78 | -0.32 | |
| P/S Ratio | 0.00 | 274.92 | 71.66 | 2.81 | 48.96 | 65.61 | 47.01 | 721.02 | 310.89 | 778.38 | 535.06 | |
| P/B Ratio | -308.76 | -0.59 | -2.23 | -0.06 | -0.20 | 0.56 | 0.26 | 0.63 | 0.54 | 0.62 | 0.60 | |
| EV/EBITDA | -64.80 | -1.57 | -8.50 | -0.22 | -0.25 | -0.21 | 0.41 | -0.58 | 0.47 | 0.42 | 1.07 | |
| EV/Revenue | 0.00 | 379.04 | 74.70 | 8.69 | 53.16 | -56.60 | -46.90 | 335.81 | -229.15 | -420.61 | -1746.86 |
Analyst Estimates & Quality
Altman Z-Score
-12.52
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $23.4M | $33.8M | $60.1M |
| Net Income | -$2.8M | -$2.1M | -$2.0M |
| EPS | $-1.18 | $-0.88 | $-0.85 |
| # Analysts (EPS) | 1 | 1 | 1 |